{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Biotech Intuition","title":"Biotech Daily - 13th October 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/a59c1bc5\"></iframe>","width":"100%","height":180,"duration":394,"description":"This digest covers key developments from BioNTech, Samsung Biologics, Johnson & Johnson, and Formycon, including Phase III readouts, a cross-border tender offer, and regulatory acceptances, alongside broader coverage across the sector. \nThis brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.","thumbnail_url":"https://img.transistorcdn.com/9CRjd85JHtM1TuR9eJILKciqKkE8Zi-g-0T-xOirVCU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZGRl/OGVlNDg2NjQ1MmUx/OTMyMjcxZmY3Zjdk/N2JiYS5qcGVn.webp","thumbnail_width":300,"thumbnail_height":300}